Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00574132 | Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) | PHASE3 | COMPLETED | 1,331 | — | — | Dec 1, 2007 | Jun 1, 2012 | Nov 25, 2013 | 251 | United States, Austria +2 |
| NCT00575055 | Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) | PHASE3 | COMPLETED | 1,121 | — | — | Dec 1, 2007 | Apr 1, 2012 | Nov 25, 2013 | 186 | United States |
| NCT00112073 | AAB-001 in Patients With Mild to Moderate Alzheimer's Disease | PHASE2 | COMPLETED | 234 | — | — | Apr 1, 2005 | Dec 1, 2008 | Mar 14, 2012 | 26 | United States |
| Arm | Type | Description |
|---|---|---|
| Bapineuzumab 0.5 mg/kg | EXPERIMENTAL | infusion every 13 weeks for a total of 6 infusions |
| Placebo Control | PLACEBO_COMPARATOR | infusion every 13 weeks for a total of 6 infusions. |
| Bapineuzumab 1.0 m/kg | EXPERIMENTAL | infusion every 13 weeks for a total of 6 infusions. |
| Placebo Dose | PLACEBO_COMPARATOR | infusion every 13 weeks for a total of 6 infusions. |
| 0.15 mg/kg active bapineuzumab | EXPERIMENTAL | - |
| 0.15 mg/kg placebo | PLACEBO_COMPARATOR | - |
| 0.5 mg/kg active bapineuzumab | EXPERIMENTAL | - |
| 0.5 mg/kg placebo | PLACEBO_COMPARATOR | - |
| 1.0 mg/kg active bapineuzumab | EXPERIMENTAL | - |
| 1.0 mg/kg placebo | PLACEBO_COMPARATOR | - |
| 2.0 mg/kg active bapineuzumab | EXPERIMENTAL | - |
| 2.0 mg/kg placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Bapineuzumab 0.5 mg/kg | DRUG | infusion every 13 weeks for a total of 6 infusions |
| Placebo Control | DRUG | given by infusion every 13 weeks for a total of 6 infusions. |
| Bapineuzumab 1.0 m/kg | DRUG | infusion every 13 weeks for a total of 6 infusions |
| bapineuzumab | DRUG | IV, Q13w |
| placebo | OTHER | IV Q13w |
Inclusion Criteria: * Diagnosis of probable AD * Age from 50 to less than 89 * Mini-Mental Status Exam score of 16-26 inclusive * Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD * Stable doses of medications (cholinesterase inhibitors and memantine allowed) * Caregiv...